Cancer Therapy

Company adds Paclitaxel Injection to its U.S. product line

Published in Women's Health Weekly, October 9th, 2003

Faulding Pharmaceutical Co. announced that it is in the process of adding Paclitaxel Injection to its line of oncology products and hopes to begin marketing the product in the United States in October.

The product is equivalent to Bristol-Myers Squibb's Taxol Injection and is a treatment for a number of cancer types including breast and ovarian.

Stuart Hinchen, president of Faulding Pharmaceutical Co., said, "The addition of Paclitaxel to our continually broadening product lines is a very exciting event because it demonstrates our commitment to meeting our customers' needs of gold standard products at a competitive price." Additionally, Hinchen noted...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2003-10-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry